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SUMMARY
What is known and objective: There is great interindividual
variability in citalopram (CIT) pharmacokinetics. We attempted
to establish a population pharmacokinetic (PPK) model of CIT
in Chinese healthy subjects, to evaluate the effect of genetic
polymorphism on CIT pharmacokinetics and to compare the
PPK and non-compartmental (NCA) assays in the estimation of
CIT bioequivalence.
Methods: Blood samples of 23 healthy subjects were collected
after administration of CIT; plasma concentration of CIT was
analysed using LC/MS-MS. CYP2C19 and CYP2D6*10 geno-
types were determined. PPK model was established by using
nonlinear mixed-effect modelling (NONMEM). The model was
evaluated using goodness-of-ﬁt plots and relative error mea-
surements. Bioequivalence of CIT was evaluated by both PPK
and NCA method.
Results and discussion: The estimated population absorption rate
constant (ka), clearance (CL/F) and volume of distribution (Vd/F)
in Chinese healthy subjects are 0.64 L/h, 12.7 L/h and 705 L,
respectively. Different CYP2C19 and CYP2D6 genotypes have
impacts on CIT pharmacokinetics. There is about 5.5% decrement
of CL/F for each CYP2C19*2 or CYP2D6*10 allele. The 90%
conﬁdence interval of CIT bioavailability obtained from NCA
and PPK model were 96.4–105.4% and 92.5–103.4%, respectively.
What is new and conclusion: The PPK of CIT is best character-
ized by a one-compartment disposition model with ﬁrst-order
absorption. CYP2C19 and CYP2D6 genotypes have impacts on
the CL/F of CIT. Bioequivalence of CIT can be estimated by both
NCA and PPK model.
WHAT IS KNOWN AND OBJECTIVE
Citalopram (CIT) is a selective serotonin reuptake inhibitor, which
is mainly used for the treatment of depression. After oral
administration, maximum plasma concentrations are seen 2–4 h
after dosing. The absolute bioavailability of an oral formulation is
about 80%.1,2 There is great interindividual variability in CIT
pharmacokinetics. It was reported that there is a 7-fold variance in
apparent oral clearance (CL/F) in patients receiving CIT
monotherapy.3,4 Hepatic metabolism is one of the most important
causes for variability in CIT pharmacokinetics. CIT is converted
into its major metabolite demethylcitalopram (DCIT) through N-
demethylation, and a further demethylation at the same site results
in didesmethylcitalopram (DDCIT), a minor secondary metabolite.
The formation of these metabolites is catalysed by the CYP2C19,
CYP2D6 and CYP3A4 isozymes.5–8 CYP3A4 is responsible for an
estimated 70% of the N-demethylation of CIT, whereas CYP2C19
contributes to about 7% of the catalysis.5 CYP2D6 plays a still
minor role in the metabolism of CIT and DCIT.6,7
Metabolic activity of CYP2C19 exhibits remarkable genetic
polymorphism. People can be grouped into CYP2C19 extensive
metabolizers (EMs) and poor metabolizers (PMs). The incidence of
PM in Chinese (13–23%) is much higher than in Caucasian (2–5%).9
CYP2C19*2 and CYP2C19*3 alleles can explain nearly all Chinese
PMs. Genetic polymorphisms of CYP2C19 on the metabolism of
CIT have been widely studied. Homozygous CYP2C19 non-
functional allele carriers have an estimated 42% reduced clearance
as compared with homozygous wild-type carriers. Lower doses of
CIT in CYP2C19 PMs were recommended.10 The frequencies of
CYP3A4 alleles (*4, *5, *6, *18A and *19) are all lower than 1% in
Chinese.11,12 The importance of these alleles on CIT therapy is
limited. CYP2D6 also shows remarkable genetic polymorphism in
the Chinese population, and the frequency of the loss-of-function
CYP2D6*10 allele in Chinese is about 37–70%.13–15
Population pharmacokinetic (PPK) study provides a quantita-
tive estimation of the interpatient variability in pharmacokinetic
response, the intrapatient variability and the inﬂuence of demo-
graphic, clinical and genetic factors on the pharmacokinetics. PPK
is also suitable for modelling pharmacokinetic responses in a
relatively large group of subjects with only relatively sparse
samples for each subject. There are few studies of CIT PPKs
especially on the inﬂuence of CYP2D6 genetic polymorphism.
The main objective of this study was to establish a PPK model
for the Chinese population and to evaluate the effects of CYP2C19
and CYP2D6 polymorphisms on CIT pharmacokinetics. We also
aimed to use the PPK model constructed to evaluate the
bioequivalence of CIT formulations.
MATERIALS AND METHODS
Subjects
This study was conducted as a randomized, open-label, compar-
ative, cross-over bioequivalence study. The protocol was approved
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by the Ethics Committee of Ruijin Hospital. The trial was in
accordance with the principles of the Declaration of Helsinki and
the guidelines of Good Clinical Practice. All subjects gave written
informed consent prior to enrolment in the study. The CYP2C19
genotype of 42 candidates was determined by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP)
assays. Subjects with CYP2C19 *1/*1, *1/*2 or *1/*3 alleles were
considered as EMs. Finally, 24 male Chinese Han volunteers (age,
25.0  2.9 years; weight, 65.2  5.0 kg) of EM genotype were
enrolled. Each subject was physically normal and had no
antecedent history of signiﬁcant medical illness or hypersensitivity
to any drugs. Their health status was judged to be normal based
on a physical examination with a screening of blood chemistry,
complete blood cell count, urinalysis and electrocardiogram before
the study. None of these subjects had taken any drugs for at least
2 weeks before the study.
Study protocol
All volunteers entered the study centre before 8:00 PM the day
before the study. After an overnight fast, they received a single
dose of 20-mg test or reference CIT tablets (reference formulation:
Ciprimil, 20-mg tablets, lot no. 2127701; H. Lundbeck A/S,
Copenhagen, Denmark; test formulation: Citalopram, 20-mg
tablets, lot no. 7B7471; Salutas Pharma GmbH, Barleben, Genr-
many) formulation with 240 mL of water at 8:00 AM. No water
was allowed 1 h prior to and 2 h after drug administration.
Standard meals were provided 4 and 10 h after dosing, respec-
tively. No other food was permitted during the ‘in-house’ period.
Xanthine-containing drinks including tea, coffee or cola were
abandoned.
Two millilitres of blood samples was collected from an
indwelling catheter in the arm into sterile EDTA anticoagulated
tube before (0 h) and 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120
and 144 h after dosing. Systolic and diastolic arterial pressure and
heart rates were recorded at each sampling time. The blood
samples were centrifuged at 3000 g for 10 min, and plasma was
separated and stored at 70 °C until analysis.
Genotyping of CYP2C19 and CYP2D6
Leucocyte DNA was extracted from blood samples by a modiﬁed
phenol–chloroform extraction assay. The obtained DNA was
dissolved in TE buffer and stored at 4 °C. CYP2C19 genotyping
was conducted by the PCR-RFLP assay according to the previous
studies with minor revision. Fragments containing CYP2C19*2
and *3 alleles were ampliﬁed. The ﬁnal 50 lL of PCR mixture
contained 50 ng of genomic DNA, 19 PCR buffer, 1.5 mM of
MgCl2, 0.2 mM of each dNTP, 0.4 lM of each primers (for
CYP2C19*2, P1: TCA GAG GCT GCT TGA TAG AAA T, P2:
AGT CAA TGA ATC ACA AAT ACG C; for CYP2C19*3, P3:
TTC ATC CTG GGC TGT GCT, P4: AGG GCT TTG GAG TTT
AGT GG. The primers were synthesized by Invitrogen Co. Ltd,
Shanghai, China) and 2 U Taq DNA polymerase (Fermentas,
Ontario, Canada). The reaction was carried out according to the
following program: 7 min of initial denaturation at 94 °C;
followed by 30 cycles of 94 °C for 45 s, 55 °C for 45 s and
72 °C for 45 s; with a ﬁnal extension at 72 °C for 7 min. PCR
products were analysed by electrophoresis with 2% agarose gels.
The ampliﬁed DNA fragments containing CYP2C19*2 and *3
allele were digested with SmaI and BamHI (TaKaRa Biotech,
Dalian, China) respectively, at 37 °C for 16 h. The digested
fragments were analysed by electrophoresis with 4% agarose
gels.
A tetra-primer method established in our laboratory was used to
determine the genotype of C100T (CYP2D6*10).15 Twenty-ﬁve
microlitres reaction system contained 50 ng DNA, 19 PCR buffer,
1.5 mMMgCl2, 0.2 mM dNTP, 0.4 lM for each of the outer and inner
primers (outer1: TCA ACA CAG CAG GTT CAC TCA CAG CA,
outer2: CTG TGG TTT CAC CCA CCA TCC AT, inner1: ACG CTG
GGC TGC ACG CTA CC, inner2: AGT GGC AGG GGG CCT GGT
GA), 0.04% Tween-20, 1.25 mM tetramethyl ammonium chloride
and 0.5 U Heat start Taq DNA polymerase (Bio Basic Co. Ltd,
Ontario, Canada). The reaction was performed according to the
following program: 15 min at 94 °C; followed by 33 cycles of 94 °C
for 30 s, 65 °C for 30 s and 72 °C for 45 s; with a ﬁnal extension at
72 °C for 7 min. PCR products were analysed by electrophoresis
with 2% agarose gels.
Determination of CIT and DICT in plasma
Plasma CIT and DCIT concentrations were analysed using a high-
performance liquid chromatography tandem mass spectrometry
(LC-MS/MS).16 Brieﬂy, to 200 lL plasma sample, 600 lL of
methanol with internal standard (desipramine) was added to
precipitate plasma protein. After vortexing for 5 min, the samples
were centrifuged at 15 493 g for 10 min. Hundred microlitres of
supernatant was mixed with 100 lL water, and 10 lL mixture
was injected into the Angilent 1200 LC system and eluted with
acetonitrile and 0.25% formic acid (30 : 70, v/v) at a ﬂow rate of
300 lL/min. The separation was carried out using a Zorbax XDB
C18 column (2.1 9 50 mm, 3.5 lm; Agilent Technologies Inc.,
USA) with temperature of 35 °C. HPLC system was coupled to an
Agilent 6410 triple quadrupole mass spectrometer (Agilent
Technologies Inc., Santa Clara, CA, USA) with an electrospray
interface in positive ionization mode. Multiple reaction monitor-
ing was used to quantify CIT (m/z 325 [M + H]+?109), DCIT
(m/z 311 [M + H]+?109) and despramine (m/z 267 [M + H]+?
208). Linearity calibration range of CIT and DCIT was 0.2–100
and 0.25–50 ng/mL, respectively. The recovery of CIT and DCIT
was 105.3% and 99.7%, respectively. The relative standard
deviation of CIT and DCIT was lower than 11.4% and 8.3%,
respectively.
Pharmacokinetic analyses
Non-compartmental (NCA) pharmacokinetic analysis. Plasma concen-
trations of CIT and DCIT obtained from subjects were analysed
using NCA assay by WinNonlin 5.01 (Pharsight Corporation,
Mountain View, CA, USA). The Cmax and the Tmax were obtained
directly from the data. Area under concentration–time curve
(AUC) was estimated by means of trapezoidal method and
extrapolation of the area to inﬁnite time.
Compartmental pharmacokinetic analysis. Structure model: Population
pharmacokinetic model of CIT was constructed using NONMEM
(Version 6; GloboMax, Hanover, MD, USA). One- and two-
compartment structure models were evaluated during model
construction. Concentration data of CIT were log-transformed to
ensure the random effects are sufﬁciently distributed around zero.
The ﬁrst-order conditional estimation method was applied for the
modelling. Model selection was based on the objective function
value (OFV), parameter estimates and standard errors. OFV is
proportional to 2 log likelihood of the relevant models. Lower
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value indicates a better model. The distribution of empirical Bayes
estimates was also important factors for model selection.
Interindividual and residual error model: The interindividual
variability of the parameters was assessed using an exponential
function: Pi ¼ TVðPiÞ  egi
where Pi was the individual value, TV(Pi) was the population
value for the parameters described in the equation and gi was the
random deviation of Pi from TV(Pi). The values of gi were
assumed to be independently normally distributed with a mean of
0 and a variance of x2.
As the concentration data were log-transformed, an additive
model was used for residual error analysis of CIT as:
lnCobs = lnCpred + e.
where Cobs is the observed concentration, Cpred is the predicted
concentration, and e is a residual error with a mean of 0 and a
variance of r2.
Covariates: Subjects’ demographic data such as age, body
weight, physiological characteristics such as clearance of create-
nine (CLcr) and genetic polymorphisms were evaluated as the
possible covariates of CIT pharmacokinetic model. The inﬂuence
of continuous covariates on the pharmacokinetic parameter TV(P)
was modelled according to the following equations:
TVðPÞ ¼ hP  ðcovariateÞ
TVðPÞ ¼ hP þ hC  ðcovariateÞ
TVðPÞ ¼ hP  ðecovariatehc Þ
TVðPÞ ¼ hP  ðcovariate/means of covariateÞhc
For CYP2C19 and CYP2D6 genotypes, discrete numbers were
given to each index: 0 and 1 for CYP2C19 *1/*1 and *1/*2 (or *1/
*3) subjects, respectively; 0, 1, 2 for CYP2D6 *1/*1, *1/*10 and
*10/*10 subjects, respectively. We also considered the inﬂuence of
CYP2C19 and CYP2D6 genotype simultaneously: 0–5 was
assigned to 2C19*1/*1- 2D6*1*1, 2C19*1/*1- 2D6*1/*10,
2C19*1/*2- 2D6*1/*1, 2C19*1/*1- 2D6*10/*10, 2C19*1/*2-
2D6*1/*10 and 2C19*1/*2- 2D6*10/*10, respectively. Pharmaco-
kinetic parameter TV(P) was modelled according to the following
equations:
TVðPÞ ¼ hP þ hC  ðcovariateÞ
TVðPÞ ¼ hP  ðecovariatehc Þ
TVðPÞ ¼ hP  hcovariate
where TV(P) is the typical value of the pharmacokinetic param-
eters, hP is the population estimation of the parameter, and hc is the
factor contributed by the covariate.
Formulation factors on the pharmacokinetics of CIT were also
tested.17 The population values of pharmacokinetic parameters for
reference and test formulations are as follows:
kaT ¼ hka  kaR
ka ¼ ð1 TRETÞ  kaR þ TRET  kaT
F1 ¼ ð1 TRETÞ  1þ TRET  FT
kaT andkaR arePPKvaluesof absorption constant of test andreference
formulation. FT is the relative bioavailability of test formulation of
CIT. TRET is the formulation indicator variable, TRET = 0 indicated
reference product and TRET = 1 indicated test product.
A forward inclusion and backward elimination techniques were
used for the ﬁnal regression model. Each candidate covariate was
screened in turn by adding it to the base model. Weighted
residuals and the change in the OFV were noted in the model-
building process. Changes in the OFV approximate the chi-square
distribution with the degrees of freedom (d.f.) equal to the number
of covariates introduced. A covariate was considered statistically
signiﬁcant when the OFV decreased by 3.84 or greater (P < 0.05,
d.f. = 1) when added to the base model (forward inclusion). The
full model included all covariates that showed a signiﬁcant
decrease in OFV. Hence, each covariate remaining in the model
was removed in turn by ﬁxing its value to zero. This procedure
was repeated until the value of the objective function failed to
increase by more than the critical value of 6.63 (P < 0.01, d.f. = 1;
backward elimination). Individual pharmacokinetic parameters,
arithmetic means and standard deviations were calculated using
the NONMEM Bayesian estimates from POSTHOC output.
Model validation: As there are relatively few subjects in this
study, the data-splitting method was not used for model testing.
Instead, the stability and performance of ﬁnal model were assessed
through an internal validation method that involved a nonpara-
metric bootstrap with resampling and replacement. In this study,
400 bootstrap samples were generated, and the PPK parameters
were estimated for each of the 400 samples using the ﬁnal model.
The mean and standard error of parameter estimates from the
bootstrap analyses were then compared with the NONMEM
estimates from the ﬁnal model.
Statistical analysis
Pharmacokinetic parameters of CIT were shown as means  stan-
dard deviations (SD). Kruskal–Wallis test was used to compare
Cmax, AUC and Cl among different CYP2C19 and CYP2D6
genotype groups. Mann–Whitney U-test was used to compare
Cmax, AUC and Cl between two CYP2D6*10 genotype groups.
P < 0.05 was considered to be statistically signiﬁcant.
Analysis of variance (ANOVA) was performed on the log-
transformed Cmax, AUC from NCA analysis. Two one-sided tests
were carried out for bioequivalence, and 90% conﬁdence intervals
(CI) were calculated. Bioequivalence was determined, if the 90% CI
of the geometric mean was within 80–125%.
RESULTS AND DISCUSSION
Genetic polymorphism of CYP2C19 and CYP2D6 on CIT
pharmacokinetics
Twenty three of 24 subjects ﬁnished the study and one subject
discontinued for personal reason. 736 CIT plasma concentrations
were obtained. In 23 subjects, there are 9 *1/*1 and 14 *1/*2
subjects for CYP2C19. There is difference in the concentration time
curve of CIT among various CYP2C19 genotypes (Fig. 1). However
the difference of CL/F between different CYP2C19 genotype was
not statistically signiﬁcant (P = 0071; Fig. 2A). Studies have
shown that the disposition of CIT is associated with the polymor-
phism of CYP2C199. Yu et al. 18 suggested gene-dose effect in
CYP2C19 CIT N-demethylation. The t1/2 and CL/F of CIT, as well
as the AUC, Cmax and Tmax of DCIT in PMs were signiﬁcantly
different from those in homozygous EMs (P < 005) and hetero-
zygous EMs (P < 005). Yin et al. 10 used CYP2C19 genotypes as
© 2013 John Wiley & Sons Ltd Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 504–511
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the covariate of CL/F in PPK modeling of CIT in 53 Chinese
patients. They found that CYP2C19 PM patient had a 429% and
333% lower CL/F than homozygous and heterozygous EM
patients, respectively. To minimize the inﬂuence of CYP2C19
genotypes on exposure to CIT, we excluded subjects carrying the
homozygous CYP2C19 mutant alleles from this study. It seemed
that the CL/F of CYP2C19 *1/*1 subjects is higher than that of *1/
*2 subjects.
There were 4 *1/*1, 7 *1/*10 and 12 *10/*10 subjects for
CYP2D6. CL/F in CYP2D6 *1/*1 group was signiﬁcantly higher
than *1/*10 and *10/*10 groups (P < 005; Fig. 2B). When
different CYP2C19 and CYP2D6 genotypes were considered
simultaneously (2C19-2D6), the pharmacokinetic parameters are
summarized in Table 1. The ratio of Cmax, AUC0–∞ of 3 CYP2D6*10
groups with CYP2C19*1/*1 genotype was 1 : 123 : 115 and
1 : 122 : 125, respectively; for CYP2C19*1/*2 group the ratios
were 1 : 118 : 124 and 1 : 148 : 193, respectively.
A previous study used human CYP3A4, CYP2C19 and CYP2D6
isozymes expressed by cDNA in the metabolism of CIT in vitro.
The results showed that CYP2C19 and CYP3A4 had much higher
Km values than CYP2D6 (166, 204 and 20 lM, respectively).
Nevertheless, the Vmax of CYP2C19 and CYP3A4 is also 10 times
higher than that of CYP2D6. Thus, intrinsic clearance values
(Vmax/Km) of CIT was similar for the three isozymes
7. CYP2D6
plays a minor role in the biotransformation of CIT due to its lower
expression level than CYP2C19 and CYP3A4. In vivo studies of
CYP2D6 polymorphism on CIT pharmacokinetics are scarce.
Sindrup et al. 6 found that AUC0–120 h and t1/2 of CYP2D6 PM
seemed higher than those of EM subjects (53038  19623 vs.
42441  10216 nmolh/L for AUC, 380  122 vs. 316  62 h
for t1/2), but the difference was not statistically signiﬁcant. On the
other hand, Herrlin et al. 19 investigated the pharmacokinetics of
the CIT, DCIT and DDCIT enantiomers in Swedish subjects. The
results suggested that clearance of DCIT but not of CIT was
inﬂuenced by CYP2D6 phenotype. It our study it seemed there is a
gene dose effect of CIT pharmacokinetics among different
CYP2D6*10 genotypes and the effect is more signiﬁcant in subjects
with CYP2C19*1/*2 genotype. It can be inferred that CYP2D6
(a)
(b)
(c)
(d)
Fig. 1. Concentration–time curve of citalopram in test and reference formulation with various CYP2C19 and CYP2D6*10 genotypes. (a, c)
various CYP2C19 genotypes of test and reference formulation; (b, d) various CYP2D6*10 genotypes of test and reference formulation.
(a) (b)
Fig. 2. Clearance (CL/F) of 23 Chinese subjects after oral administration of 20-mg citalopram among different CYP2C19 (a) and
CYP2D6*10 (b) genotypes. °: Outliers.
© 2013 John Wiley & Sons Ltd Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 504–511
507
Estimation of CYP2D6*10 genotypes on citalopram disposition B. Chen et al.
genetic polymorphism may play a more important role in CIT
metabolism in subjects with poor CYP2C19 and/or CYP3A4
metabolic activity.
PPK model of CIT and the inﬂuence of genetic polymorphism
Different structure models (1 and 2 compartment model, with or
without lag time) were tested. The best structural model consisted
of a 1-compartment model with a single ﬁrst-absorption process
and ﬁrst-order elimination process. The absorption rate constant
(ka) for the 23 healthy subjects was 064  0081 L/h, but with
large inter-individual variation (622%). Tmax obtained using NCA
method also showed great variability (Tmax: 2~12 h). Yin et al.
10
tested different ka (025–25 L/h), and found that 075 L/h was the
best, an estimate comparable to that obtained in our study.
Although CIT is completely absorbed in the intestine20, the
duration of absorption shows great inter-individual variability.
In previous studies, Bies et al. 21 and Friberg et al. 22 found great
inter-individual variability of ka (CV=451% and 510%, respec-
tively).
Since CIT was administered orally, the clearance (CL/F) and
distribution volume (Vd/F) included bioavailability (F). CL/F
(mean  SE) was estimated to be 127  049 L/h; the Vd/F was
705  193 L (Table 2). The Vd/F estimate in the present study is
lower than estimates reported by investigators in Denmark
(13102  16566 L)2, Sweden (1364  155 L)23 and Australia
(1297 L)22, but is comparable to that reported for Chinese subjects
(670  244 L)10. There may be an ethnic difference in Vd/F of CIT
between Caucasian and Chinese subjects.
A previous study in Caucasians21 found that body weight and
age inﬂuence CL/F and Vd/F signiﬁcantly. The CL/F increased
014 L/h for every kilogram of body weight and decreased
023 L/h for every year of age. The study of Yin et al. 10 in
Hong-Kong Chinese patients also found that CL/F increased by an
estimated 011 L/h for every kilogram body weight. We tested
body weight, age and CLcr as covariates, but none neither of these
factors was signiﬁcant. This may be due to that the subjects
included in this study being healthy with normal renal function
and similar body weight and age.
When CYP2C19 genotype was tested as a covariate, CL/F of
CYP2C19*1/*2 subjects was about 14% lower than that of *1/*1
subjects. However, the OFV decreased by only about 40, CYP2C19
is not a signiﬁcant covariate with CL/F. The result is consistent
with previous pharmacokinetic studies on CIT which showed that
CYP2C19 *1/*1 (homozygous EMs), *1/*2 or *1/*3 (heterozy-
gous EMs) can be categorized as one group.
We classiﬁed subjects according to both CYP2C19 and CYP2D6
genotype. 6 different genetic polymorphism groups, 0–5 could be
identiﬁed. The genotype was used as a covariate for CIT CL/F.
OFV decreased by 138, and inter-individual variability of CL/F
decreased from 230% to 180% (Table 2). Subjects with
CYP2D6*10/*10 and CYP2C19*1/*2 genotype had CL/F 274%
lower than subjects with CYP2D6*1/*1 and CYP2C19*1/*1
genotypes. The results suggest that CYP2D6*10 allele has an
impact on the pharmacokinetics of CIT, especially in subjects with
a CYP2C19 defective allele.
Model validation
The assessment of the predictive performance of the ﬁnal model is
represented in scatter plots of observed CIT concentration (DV)
versus population predicted CIT concentrations (PRED, Fig. 3A)T
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and individual predicted CIT concentrations (IPRE, Fig. 3B);
weighted residual (WRES) vs. PRED (Fig. 3C) and time (Fig.
3D). Residuals of most concentration data were randomly distrib-
uted within 2 standard deviations (SD), which designated good
agreement. The average bias of CIT was 319% (95% conﬁdence
interval (CI): 261–377%). Some lack of ﬁt is evident in the plot.
Only 20 out of the 736 samples are out of 2 SD.
392 of the 400 bootstrap runs successfully, two runs terminated
with rounding errors, and the other six runs terminated without
covariate step. The bootstrap indicated good results with the
results obtained from ﬁnal model. The results of ka, CL/F and Vd/
F calculated by NONMEM are in the center of histogram of 392
runs of bootstraps (Fig 4).
Bioequivalence analysis by NCA and PPK modeling
Although the most popular method for the assessment of
bioequivalence of different formulations is NCA, previous studies
suggested that a PPK model may be better for studying drugs with
more complicated plasma concentration-time proﬁles and may be
useful for studying bioequivalence study in patients24. With the
PPK method, a set of parameter estimates can be obtained. For
example, ka between different formulations can be compared using
the PPK approach. Besides, the Cmax values obtained by PPK are
likely to be less biased than those observed using the NCA
method. With Bayesian methodology, bioequivalence can be
assessed 17, 25. In this study, NCA analysis showed the 90% CI
of the AUC0–∞ and Cmax are within 80–125%, which indicated
bioequivalence of the test drug to the reference drug. Bioequiva-
lence estimation through PPK modeling assay showed similar
results. We obtained individual Cmax and AUC of the reference
and test formulations of CIT using the Bayesian method. The 90%
CIs of these parameters are similar to those obtained using NCA
(Table 3). Tmax obtained using NCA and PPK method was
compared by Wilcoxon test, and both methods showed that there
was no difference between the reference formulation and the test
Table 2. The citalopram pharmacokinetic parameters obtained by nonlinear mixed-effect modelling
Basic model Final model
BootstrapMean (SE) 95% CI Mean (SE) 95% CI
Parameters (h)
CL/F (h1) (L/h) 12.7 (0.49) 12.5–12.9 15.6 (0.43) 15.4–15.8 16.0 (0.69)
Vd/F (h2) (L) 705 (19.3) 697.1–712.9 705 (19.2) 697.2–712.8 699 (18.8)
ka (h3) (L/h) 0.64 (0.081) 0.61–0.67 0.63 (0.081) 0.60–0.66 0.61 (0.058)
Genotpe (h4) NA NA 0.054 (0.017) 0.061 to 0.047 0.25 (0.034)
Inter-individual variability (g)
xCL, % 23.0 (11.6) 18.3–27.7 18.0 (10.0) 13.9–22.1 14.8 (1.71)
xVd, % 8.89 (8.41) 5.5–12.3 9.29 (8.31) 5.9–12.7 10.7 (2.31)
xka, % 62.2 (32.2) 49.0–75.4 62.4 (32.4) 49.2–75.6 59.9 (5.5)
Residual error (e)
r, % 32.1 (15.0) 26.0–38.2 31.9 (14.1) 26.1–37.7 32.4 (3.35)
Objective function value 696.2 710.0
As interindividual variability of Vd/F is lower than 0.01%, it was ﬁxed to 0.
(a) (b)
(c) (d)
Fig. 3. Goodness-of-ﬁt of citalopram population pharmacokinetic model. (a) Population-predicted concentration (PRED) vs. observed
concentration (DV); (b) individual-predicted concentration (IPRE) vs. DV; (c) Weighted residual error (WRES) vs. PRED; (d) WRES vs. time.
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formulation. We also assessed the bioequivalence by introducing
the formulation factors. The ratio of ka between test and reference
formulation (hka) and bioavailability (F1) of test drug was used to
assess potential differences between the 2 CIT formulations on the
extent of absorption and the exposure. The point estimate (with
90% CI) for hka and FT were 1060% (848–1272%) and 991%
(894%~1089%). It can be inferred that test and reference formula-
tions had a similar rate of absorption and exposure.
WHAT IS NEW AND CONCLUSIONS
In this study, we studied the inﬂuence of CYP2C19 and
CYP2D6*10 genotypes on the pharmacokinetic characteristics
of CIT in healthy Chinese subjects by using PPK method for the
ﬁrst time. We found pharmacokinetics of CIT in Chinese
subjects is best characterized by a one-compartment disposition
model with ﬁrst-order absorption, CYP2C19 and CYP2D6*10
alleles play signiﬁcant roles in the metabolism of CIT. CIT
pharmacokinetic parameter values (e.g. CL/F, Vd/F, AUC, etc.)
estimated using NONMEM are similar to those obtained with
NCA analysis. The PPK method could be used to assess the
bioequivalence of CIT.
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Fig. 4. Histogram of ka, CL/F and Vd/F of citalopram from 392 bootstraps. Vertical line means the estimated parameters from population
pharmacokinetic model we established.
Table 3. The bioequivalence of citalopram obtained from non-compartmental and nonlinear mixed-effect modelling (NONMEM) assay
Non-compartment NONMEM
Test Reference BA (%) Test Reference BA (%)
Cmax (ng/mL) 32.3  5.9 33.1  7.4 92.5–103.6 26.2  2.5 26.4  3.0 92.9–101.1
AUC (ng h/mL) 1595  381 1648  504 96.4–105.4 1575  265 1616  363 92.5–103.4
Tmax (h) 3.22  2.26 3.60  1.44 2.77  1.39 2.86  0.91
hka 106.0% (84.8–127.2%)
FT 99.1% (89.4–108.9%)
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